P2RY2

P2Y purinoceptor 2 · P41231 · P2RY2 on Sugi Atlas →

71,947 patent compounds predicted against P2RY2, 43,583 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Uridine (SCHEMBL338288)	0.65	16/20
SCHEMBL150273	0.49	16/20
SCHEMBL8003	0.68	15/20
SCHEMBL48209	0.68	15/20
Cytarabine 5'-Phosphate (SCHEMBL27306)	0.67	15/20
Uridine Triphosphate (SCHEMBL166686)	0.61	15/20
Uridine Triphosphate (SCHEMBL317396)	0.90	14/20
Biotin (SCHEMBL381578)	0.51	14/20
Uridine Triphosphate (SCHEMBL317395)	0.90	13/20
Cystetine Triphosphate (SCHEMBL104629)	0.80	13/20
Cystetine Triphosphate (SCHEMBL104630)	0.80	13/20
Cystetine Triphosphate (SCHEMBL105273)	0.80	13/20
Cystetine Triphosphate (SCHEMBL315351)	0.80	13/20
SCHEMBL376515	0.80	13/20
SCHEMBL376516	0.80	13/20
SCHEMBL42134	0.68	13/20
SCHEMBL111359	0.68	13/20
SCHEMBL116642	0.67	13/20
SCHEMBL156694	0.65	13/20
SCHEMBL109120	0.63	13/20

Clinical trials — most relevant to P2RY2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine	PHASE4	COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR	PHASE4	NOT_YET_RECRUITING
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects	PHASE4	COMPLETED
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment	PHASE4	COMPLETED
Ticagrelor in Remote Ischemic Preconditioning Study	PHASE4	COMPLETED
Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI	PHASE4	UNKNOWN
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS	PHASE3	COMPLETED
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy	PHASE2	RECRUITING
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects	PHASE1	COMPLETED
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese	PHASE1	COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults	EARLY_PHASE1	COMPLETED
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy	nan	UNKNOWN
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)	nan	ACTIVE_NOT_RECRUITING
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention	nan	COMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling	nan	COMPLETED
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome	nan	COMPLETED
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes	nan	COMPLETED
Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)	nan	COMPLETED
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients	nan	RECRUITING
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES	nan	UNKNOWN
Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RY2 binder may also engage these)

Protein	Name	Similarity
Q5YA25	—	1.000	Q5YA25 →
P35383	—	0.999	P35383 →
P41232	—	0.996	P41232 →
P2RY4	P2Y purinoceptor 4	0.988	landscape →
O35811	—	0.985	O35811 →
Q9JJS7	—	0.980	Q9JJS7 →
Q63371	—	0.979	Q63371 →
P2RY6	P2Y purinoceptor 6	0.979	landscape →
Q9ERK9	—	0.978	Q9ERK9 →
Q86VZ1	—	0.962	Q86VZ1 →
P58825	—	0.953	P58825 →
LTB4R	Leukotriene B4 receptor 1	0.952	landscape →
Q99678	—	0.951	Q99678 →
P49660	—	0.951	P49660 →
Q99PE4	—	0.951	Q99PE4 →
GPR35	G-protein coupled receptor 35	0.950	landscape →
Q3T181	—	0.949	Q3T181 →
SSTR3	Somatostatin receptor type 3	0.948	landscape →
Q9R0Q2	—	0.947	Q9R0Q2 →
P55086	—	0.947	P55086 →
SSTR4	Somatostatin receptor type 4	0.947	landscape →
Q8HYC3	—	0.946	Q8HYC3 →
O88855	—	0.946	O88855 →
Q76EI6	—	0.946	Q76EI6 →
Q56UD9	—	0.946	Q56UD9 →
Q5KSK8	—	0.946	Q5KSK8 →
A7YY44	—	0.946	A7YY44 →
P30937	—	0.946	P30937 →
P30936	—	0.946	P30936 →
FFAR2	Free fatty acid receptor 2	0.945	landscape →